Schizophrenia Research
Volume 56, Issue 1 , Pages 11-17 , 1 July 2002

Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine

Received 30 September 2000 ,Revised 26 March 2001 ,Accepted 26 March 2001.

References 

  1. Angelopoulos E, Markianos M, Daskalopoulou E, Tzemos J, Stefanis C. Neuroendocrine responsivity to clomipramine challenge test in neuroleptic naı̈ve psychotic patients before and after treatment with haloperidol. Eur. Psychiatry. 1997;12:362–366
  2. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96
  3. Coccaro EF, Kavoussi RJ, Oakes M, Cooper TB, Hauger R. 5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacology. 1996;126:24–30
  4. Crawford AM, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo on serum prolactin levels. Schizophr. Res. 1997;26:41–45
  5. Curtis VA, Wright P, Reveley A, Kerwin R, Lucey JV. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. Br. J. Psychiatry. 1995;166:642–646
  6. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 1992;49:538–544
  7. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ. The effects of intravenous clomipramine on neurohormones in normal subjects. J. Clin. Endocrinol. Metab. 1989;68:632–637
  8. Golden RN, Hsiao JK, Lane E, Ekstrom D, Rogers S, Hicks R, et al. Abnormal neuroendocrine responsivity to acute IV clomipramine challenge in depressed patients. Psychiatry Res. 1990;31:39–47
  9. Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori T, Meltzer HY. Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. J. Neural Transm. 1987;68:227–240
  10. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C. Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology. 1993;112:S90–S94
  11. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry. 1998;155:921–928
  12. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry. 1999;156:286–293
  13. Kolakowska R, Braddock L, Wiles D, Franklin M, Gelder M. Neuroendocrine tests during treatment with neuroleptic drugs. I. Plasma prolactin response to haloperidol challenge. Br. J. Psychiatry. 1981;139:400–404
  14. Laakmann G, Gugath M, Kuss HJ, Zygan K. Comparison of growth hormone and prolactin stimulation induced by clomipramine and desipramine in man in connection with clomipramine metabolism. Psychopharmacology. 1984;82:62–67
  15. Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BPR, van Royen EA. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res. Neuroim. Sect. 1999;92:33–44
  16. Lemus CZ, Lieberman JA, Johns CA, Mayerhoff DI, Pollack S, Cooper TB, et al. Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients. Biol. Psychiatry. 1991;29:691–694
  17. Markianos M, Sakellariou G, Bistolaki E. Prolactin responses to haloperidol in drug-free and treated schizophrenic patients. J. Neural Transm. 1991;83:37–42
  18. Markianos M, Hatzimanolis J, Lykouras L. Switch from neuroleptics to clozapine does not influence pituitary–gonadal axis hormone levels in male schizophrenic patients. Eur. Neuropsychopharmacol. 1999;9:533–536
  19. Markianos M, Hatzimanolis J, Lykouras L. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone. Psychiatry Res. 1999;89:115–122
  20. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS. Effect of clozapine on human serum prolactin levels. Am. J. Psychiatry. 1979;136:1550–1555
  21. Mohr P, Horacek J, Motlova L, Libiger J, Czobor P. Effects of haloperidol treatment on prolactin response to d-fenfluramine challenge in acute schizophrenia. Psychopharmacology. 1999;141:322–325
  22. Ninan I, Kulkarni SK. Partial agonistic action of clozapine at dopamine D2 receptors in dopamine depleted animals. Psychopharmacology. 1998;135:311–317
  23. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects — a double-blind PET study of schizophrenic patients. Biol. Psychiatry. 1993;33:227–235
  24. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry. 1995;152:1444–1449
  25. Owen RR, Gutierrez-Esteinou R, Hsiao J, Hadd K, Benkelfat C, Lawlor BA, et al. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch. Gen. Psychiatry. 1993;450:636–644
  26. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr. Res. 1999;35:S67–S73
  27. Raap DK, Van de Kar LD. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci. 1999;65:1217–1235
  28. Raedler TJ, Knable MB, Lafargue T, Urbina RA, Egan FE, Pickar D, et al. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res. Neuroim. Sect. 1999;90:81–90
  29. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry. 1999;60(Suppl. 10):5–14
  30. Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezavas L, Barnas C, et al. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology. 1999;141:175–181

PII: S0920-9964(01)00221-3

doi: 10.1016/S0920-9964(01)00221-3

Schizophrenia Research
Volume 56, Issue 1 , Pages 11-17 , 1 July 2002

Article Tools

* Image Usage & Resolution